文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

快速药敏检测配合含氟喹诺酮类结核通用方案的临床影响:马尔可夫模型

Clinical Impact of Rapid Drug Susceptibility Testing to Accompany Fluoroquinolone-Containing Universal Tuberculosis Regimens: A Markov Model.
PubMed 文献 · Clin Infect Dis · 2020-01-01

研究用马尔可夫状态转换模型模拟10万名接受含氟喹诺酮类新方案治疗的结核成人,比较不做氟喹诺酮药敏、全民药敏与仅对利福平耐药者药敏三种策略的临床结局与资源利用。结果显示氟喹诺酮药敏可改善患者结局,在高风险人群和较弱方案中尤为重要;在氟喹诺酮耐药广泛流行时应优先采用全民策略。

要点

  • 氟喹诺酮药敏检测可提高氟喹诺酮耐药结核的治愈率
  • 仅对利福平耐药者检测时,南非每治愈1例需50次检测,东南亚需44次
  • 由靶向扩至全民药敏时,南非每增加1例治愈需3500次检测,东南亚需410次

核心结论

  • 氟喹诺酮药敏检测改善患者结局,对高风险人群和较弱方案尤为重要。
  • 在氟喹诺酮耐药广泛流行的地区,全民药敏策略更受支持。

研究设计与样本

  • 构建含10万名接受含氟喹诺酮类新方案治疗的结核成人的马尔可夫状态转换模型。
  • 比较不做氟喹诺酮药敏、全民氟喹诺酮药敏与仅对利福平耐药者做氟喹诺酮药敏三种策略。
  • 设置氟喹诺酮耐药与利福平耐药相关性较强(南非)和较弱(东南亚)两种情景,并对其他情景与方案特征做敏感性分析。

主要发现

  • 相对不做氟喹诺酮药敏,靶向药敏使氟喹诺酮耐药结核治愈率在南非提高7.5%(IQR 6.7%-9.2%),在东南亚提高1.7%(IQR 0.7%-2.5%)。
  • 利福平敏感结核中少见的氟喹诺酮耐药占氟喹诺酮耐药结核的50%(南非)和83%(东南亚)。
  • 全民药敏较靶向药敏使氟喹诺酮耐药结核治愈率在南非进一步提高3.4%(IQR 2.3%-5.4%),在东南亚提高5.8%(IQR 5.1%-6.3%)。
  • 靶向药敏下每治愈1例额外患者需检测50次(IQR 42-70,南非)和44次(IQR 37-51,东南亚)。
  • 由靶向扩至全民药敏时,每增加1例治愈需检测3500次(IQR 2300-5500,南非)和410次(IQR 370-450,东南亚)。

关键数值与推荐

  • 靶向氟喹诺酮药敏:南非每治愈1例额外患者需50次检测(IQR 42-70),东南亚需44次(IQR 37-51)。
  • 靶向扩至全民氟喹诺酮药敏:南非每增加1例治愈需3500次检测(IQR 2300-5500),东南亚需410次(IQR 370-450)。
  • 靶向药敏使氟喹诺酮耐药结核治愈率提高:南非7.5%(IQR 6.7%-9.2%),东南亚1.7%(IQR 0.7%-2.5%)。
  • 全民药敏在靶向基础上进一步提高氟喹诺酮耐药结核治愈率:南非3.4%(IQR 2.3%-5.4%),东南亚5.8%(IQR 5.1%-6.3%)。

临床怎么用

  • 对接受含氟喹诺酮类方案的结核患者开展氟喹诺酮药敏检测以指导治疗。
  • 在氟喹诺酮耐药广泛流行的地区优先考虑全民氟喹诺酮药敏策略。
  • 可先对利福平耐药等高风险人群做靶向药敏,再根据本地耐药流行情况决定是否扩展。

局限性

  • 结果为马尔可夫模型模拟,依赖情景假设与参数设定。
  • 仅模拟南非与东南亚两种耐药相关性情景,外推至其他地区需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To appropriately treat tuberculosis (TB) with regimens that combine novel and older drugs, evidence-based, context-specific strategies for drug-susceptibility testing (DST) will be required. METHODS: We created a Markov state-transition model of 100 000 adults with TB receiving a novel, fluoroquinolone (FQ)-containing regimen. We estimated clinical outcomes and resource utilization with no FQ-DST, universal FQ-DST, or FQ-DST only for patients with rifampin-resistant TB ("targeted FQ-DST"). We considered scenarios of stronger (South Africa) and weaker (Southeast Asia) correlation of fluoroquinolone resistance with rifampin resistance, with sensitivity analysis for other setting and regimen characteristics. RESULTS: Relative to no FQ-DST, targeted FQ-DST increased cure of FQ-resistant TB by 7.5% (interquartile range [IQR], 6.7%-9.2%) in South Africa and 1.7% (IQR, 0.7%-2.5%) in Southeast Asia. However, rare FQ resistance among the more prevalent rifampin-susceptible TB accounted for 50% of FQ-resistant TB in South Africa and 83% in Southeast Asia. As a result, universal FQ-DST further increased cure of FQ-resistant TB by 3.4% (IQR, 2.3%-5.4%) in South Africa and 5.8% (IQR, 5.1%-6.3%) in Southeast Asia. With targeted FQ-DST, 1 additional patient was cured per 50 (IQR, 42-70) tests in South Africa and 44 (IQR, 37-51) in Southeast Asia. When expanding from targeted to universal FQ-DST, 1 additional cure required 3500 (IQR, 2300-5500) tests in South Africa and 410 (IQR, 370-450) in Southeast Asia. CONCLUSIONS: FQ-DST improved patient outcomes and was particularly important for high-risk patient groups and less robust regimens. A universal strategy was favored in generalized epidemics of fluoroquinolone resistance.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kendall EA, Malhotra S, Cook-Scalise S, et al. Clinical Impact of Rapid Drug Susceptibility Testing to Accompany Fluoroquinolone-Containing Universal Tuberculosis Regimens: A Markov Model. Clin Infect Dis. 2020. PMID: 31813958. doi:10.1093/cid/ciz1179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。